Eligard: leuprolide acetate in a novel sustained-release delivery system
Reported by ScienceDirect.com. Read the original →
The headline indicates that the article discusses Eligard, which contains leuprolide acetate, and highlights its novel sustained-release delivery system. The focus appears to be on the formulation and delivery method of this compound.
Summarised by a model from ScienceDirect.com's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.
On file here
Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.
- Overall Survival of Patients With PSA-Recurrent Prostate Cancer: Long-Term Analysis of a Randomized Phase 2 Trial of pTVG-HP DNA Vaccine Versus Placebo.Human · RCT · n=97 · 2026
- 24-week home-based walking program in the early adjuvant setting in breast cancer patients who receive aromatase inhibitor endocrine therapy: lessons learned from the SAKK 95/17 WISE prospective, randomized, multicenter trial.Human · RCT · n=320 · 2026
- GnRH-receptor antagonism as a targeted approach to reproductive dysfunction in polycystic ovary syndrome.Human · RCT · n=18 · 2026
What the headline doesn't tell you
- Leuprorelin has 34 studies on file, 22 of them in humans, the newest published 2026.
Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.